FDA
-
-
-
-
-
-
-
Beam Therapeutics publishes sickle cell therapy data in medical journal
-
-
-
-
-
-
-
Beam Therapeutics Inc (BEAM) PT Raised to $47 at BofA Securities
-
-
-
-
-
-
-
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
-
-
-
-
-
-
-
Beam Therapeutics Inc. (BEAM) Granted FDA Orphan Drug Designation for BEAM-101
-
-
-
-
-
-
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
-
-
-
-
-
-
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
-
-
-
-
-
-
-
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
-
325,825 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

